N/A
N=140
Noradrenergic Activity and Attention
Aging
Bottom Line
View on ClinicalTrials.gov: NCT05120713 ↗Enrolled (actual)
140
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker — 3.8; 4.4; 3.6; 4.5 percentage of first saccades
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Southern California
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker |
3.8; 4.4; 3.6; 4.5 | — |
Summary
Older adults demonstrate increased distractibility by task-irrelevant information which contributes to general cognitive impairment. However, it is yet unclear how changes in noradrenergic activity during aging influences attentional control. In the current study, tonic noradrenergic activity will be increased or decreased to investigate its behavioral and neural effects on attentional control.
Eligibility Criteria
Inclusion Criteria
- Fluent in English
- Aged between 18-35 or 50-80
- Have normal or corrected-to-normal vision and hearing, and normal color vision
- Have a mobile phone and email address
Exclusion Criteria
- Non-English speakers
- Currently practicing any relaxation, meditation, or breathing technique for more than an hour per week
- Have participated in studies measuring attentional capture in the past year
- Experiencing symptoms of dementia
Data sourced from ClinicalTrials.gov (NCT05120713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.